Intestinal failure-associated liver disease in hospitalised children

Objective and aim Liver disease is a potentially life-threatening complication of intravenous/parenteral nutrition (PN). Our aim was to determine the incidence, aetiology and outcome of intestinal failure-associated liver disease (IFALD) in hospitalised children treated with long-term PN (>27 day...

Full description

Saved in:
Bibliographic Details
Published in:Archives of disease in childhood 2012-03, Vol.97 (3), p.211-214
Main Authors: Pichler, Judith, Horn, Venetia, Macdonald, Sarah, Hill, Susan
Format: Article
Language:English
Subjects:
Adolescent
Age
Age Factors
Biological and medical sciences
Care and treatment
Child
Child, Preschool
Children
complications
Death
Disease Progression
Ethics
Female
Gastroenterology. Liver. Pancreas. Abdomen
General aspects
Hospitalization
Hospitals
Humans
Infant
Infant, Newborn
Length of Stay - statistics & numerical data
Lipids
Liver
Liver diseases
Liver Diseases - etiology
Liver Function Tests - methods
Malabsorption Syndromes - complications
Malabsorption Syndromes - therapy
Male
Medical prognosis
Medical sciences
Miscellaneous
Mortality
Neonates
Nutrition
Other diseases. Semiology
Parenteral nutrition
Parenteral Nutrition - adverse effects
Parenteral Nutrition - methods
Patients
Prevention and actions
Prognosis
Public health. Hygiene
Public health. Hygiene-occupational medicine
Reviews
Sepsis
Severity of Illness Index
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
survival
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective and aim Liver disease is a potentially life-threatening complication of intravenous/parenteral nutrition (PN). Our aim was to determine the incidence, aetiology and outcome of intestinal failure-associated liver disease (IFALD) in hospitalised children treated with long-term PN (>27 days). Methods Over 4 years all long-term intestinal failure (IF) patients were reviewed for the possible predisposing factors of age, diagnosis, PN lipid, sepsis, length of PN treatment and length of hospitalisation. Outcome measures were IFALD incidence, severity and prognosis. Results Of 60/279 (22%) children aged 0–18 years who developed IFALD, 13 (5%) progressed to type 3/end stage disease. IFALD was associated with younger age (p=0.03), longer treatment (p
ISSN:0003-9888
1468-2044
DOI:10.1136/archdischild-2011-300274